Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Cripto-1 expression in patients with clear cell renal cell carcinoma is associated with poor disease outcome

Fig. 3

Serum level of CR-1 in ccRCC patients. a Comparison of serum CR-1 levels in healthy controls (n = 35) and ccRCC patients (n = 38) using ELISA. Horizontal bars represent the mean. P value was calculated using the Mann–Whitney U-test, ***P < 0.001. b comparison of CR-1 concentration stratified by Fuhrman grade (≤2 vs  > 2), tumor size (≤7 vs  > 7 cm), and TNM stage (I-IV). *P < 0.05, **P < 0.01 by Mann–Whitney U-test; ***P < 0.001 by Kruskal–Wallis test. c Receiver operating characteristic (ROC) curve analysis of serum CR-1 for distinguishing patients with ccRCC from healthy controls. d Comparison between CR-1 serum concentrations and CR-1 expression in ccRCCs. The CR-1 expression levels are presented as IHC scores. Linear correlation is examined using Pearson’s correlation analysis (Pearson coefficient 0.735, P < 0.001). e At the fourth week after surgery, the serum CR-1 levels were remarkably decreased compared with their preoperative serum. ***P < 0.001 by Student’s paired t-test. f In 10 patients with documented recurrence, the serum CR-1 were increased again to the preoperative levels. ***P < 0.001 by Student’s paired t-test. P = 0.621 by Mann–Whitney U-test

Back to article page